Angiogenic Potential of Small Extracellular Vesicles Produced by Stimulated Mesenchymal Stromal Cells Under Hypoxic Conditions
Abstract
Regenerative vascular medicine research has positioned mesenchymal stromal cells (MSCs) as a leading candidate to treat ischemic diseases. Recent studies have highlighted the emerging role of small extracellular vesicles (sEVs) produced by MSCs in their own potential. This study explores a strategy to improve the angiogenic potential of MSCs through the acquisition of endothelial features. Umbilical cord Wharton's jelly MSCs were cultured in fetal bovine serum-free endothelial growth medium under hypoxic conditions (SH-MSCs). sEVs were characterised by a multimodal approach: visualisation, count and particle size distribution, sEVs surface antigen, proangiogenic potential and ability to internalise into recipient cells. Compared with MSCs, SH-MSCs exhibited significant morphological and phenotypical change characterised by the up-regulation of CD31 and CD144 mRNA as well as a marked increase in sEVs secretion. MSC-and SH-MSC-derived sEVs had the capacity to internalise into endothelial cells, myoblasts and macrophages; exhibited a strong proangiogenic effect in vitro, particularly in promoting endothelial cell proliferation and pseudotube formation, likely due to an enriched cargo of angiogenic factors. These results highlight the dual benefit of hypoxia conditioning and endothelial differentiation of MSCs to optimise the angiogenic potential of their secreted sEVs, thus paving the way for innovative regenerative therapies in ischemic diseases.
Related
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tendon Regeneration: Insights into Inflammatory and Angiogenesis Modulation
- Circulating angiogenic T cells as potential immune-vascular biomarkers associated with disease activity in axial spondyloarthritis
- Comment on “Mapping photoisomerization dynamics on a three-state model potential energy surface in bacteriorhodopsin using femtosecond stimulated Raman spectroscopy” by Z. Wang, Y. Chen, J. Jiang, X. Zhao and W. Liu, Chem. Sci. , 2025, 16 , 3713
- Design and validation of a GMP-compliant manufacturing platform of extracellular vesicles from mesenchymal stromal cells
- Small extracellular vesicle-enriched preparations derived from genetically modified multipotent mesenchymal stromal cells promote fibroblast proliferation and extracellular matrix remodeling in vitro
BibTeX
@article{serhal2026angiogenic,
title = {{Angiogenic Potential of Small Extracellular Vesicles Produced by Stimulated Mesenchymal Stromal Cells Under Hypoxic Conditions}},
author = {Nada Serhal and Bertrand Brassart and Lise Nannan and Sandra Audonnet and Christine Terryn and Gaël Poitevin and Pascale Cornillet‐lefebvre and Florine Dubuisson and Hélène Peyret and Philippe Nguyen and Claire Tournois},
journal = {Journal of Extracellular Biology},
year = {2026},
month = sep,
doi = {10.1002/jex2.70105},
url = {https://hal.science/hal-05764026v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Angiogenic Potential of Small Extracellular Vesicles Produced by Stimulated Mesenchymal Stromal Cells Under Hypoxic Conditions
AU - Nada Serhal
AU - Bertrand Brassart
AU - Lise Nannan
AU - Sandra Audonnet
AU - Christine Terryn
AU - Gaël Poitevin
AU - Pascale Cornillet‐lefebvre
AU - Florine Dubuisson
AU - Hélène Peyret
AU - Philippe Nguyen
AU - Claire Tournois
PY - 2026
DA - 2026/09/25
JO - Journal of Extracellular Biology
DO - 10.1002/jex2.70105
UR - https://hal.science/hal-05764026v1
AB - Regenerative vascular medicine research has positioned mesenchymal stromal cells (MSCs) as a leading candidate to treat ischemic diseases. Recent studies have highlighted the emerging role of small extracellular vesicles (sEVs) produced by MSCs in their own potential. This study explores a strategy to improve the angiogenic potential of MSCs through the acquisition of endothelial features. Umbilical cord Wharton's jelly MSCs were cultured in fetal bovine serum-free endothelial growth medium under hypoxic conditions (SH-MSCs). sEVs were characterised by a multimodal approach: visualisation, count and particle size distribution, sEVs surface antigen, proangiogenic potential and ability to internalise into recipient cells. Compared with MSCs, SH-MSCs exhibited significant morphological and phenotypical change characterised by the up-regulation of CD31 and CD144 mRNA as well as a marked increase in sEVs secretion. MSC-and SH-MSC-derived sEVs had the capacity to internalise into endothelial cells, myoblasts and macrophages; exhibited a strong proangiogenic effect in vitro, particularly in promoting endothelial cell proliferation and pseudotube formation, likely due to an enriched cargo of angiogenic factors. These results highlight the dual benefit of hypoxia conditioning and endothelial differentiation of MSCs to optimise the angiogenic potential of their secreted sEVs, thus paving the way for innovative regenerative therapies in ischemic diseases.
SN - 2768-2811
ER -